Back in March 2020, not long after the coronavirus pandemic was declared, Mike Stathis of AVA Investment Analytics held two special webinars to discuss investment ideas. Although he was bullish on the drug and biopharma stocks, he pointed out that the big winners would be smaller companies that would be successful in coming up with a vaccine.
Mike pointed out the risks in investing in small cap biotechnology stocks that had nothing going on.
But he recommended investing in Moderna (MRNA) even though it was a new company because he believed the company had substantial potential even if it was unable to produce a vaccine for the coronavirus.
Note that he did not recommend any other biotechnology stocks, so his hit-miss ratio was 100%.
So how has Moderna performed since March 2020?
It has soared by as much as 1500%.
We have reserved access to these March 2020 webinars to Members and Research Clients.
Restrictions Against Reproduction: No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without the prior written permission of the copyright owner and the Publisher.
These articles and commentaries cannot be reposted or used in any publications for which there is any revenue generated directly or indirectly. These articles cannot be used to enhance the viewer appeal of any website, including any ad revenue on the website, other than those sites for which specific written permission has been granted. Any such violations are unlawful and violators will be prosecuted in accordance with these laws.
Article 19 of the United Nations' Universal Declaration of Human Rights: Everyone has the right to freedom of opinion and expression; this right includes freedom to hold opinions without interference and to seek, receive and impart information and ideas through any media and regardless of frontiers.
This publication (written, audio and video) represents the commentary and/or criticisms from Mike Stathis or other individuals affiliated with Mike Stathis or AVA Investment Analytics (referred to hereafter as the “author”). Therefore, the commentary and/or criticisms only serve as an opinion and therefore should not be taken to be factual representations, regardless of what might be stated in these commentaries/criticisms. There is always a possibility that the author has made one or more unintentional errors, misspoke, misinterpreted information, and/or excluded information which might have altered the commentary and/or criticisms. Hence, you are advised to conduct your own independent investigations so that you can form your own conclusions. We encourage the public to contact us if we have made any errors in statements or assumptions. We also encourage the public to contact us if we have left out relevant information which might alter our conclusions. We cannot promise a response, but we will consider all valid information.